Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Mets from NSCLC
“We are pleased to announce the completion of enrollment in the METIS study, our fourth pivotal study to complete enrollment in the last 17 months and our second study addressing non-small cell lung cancer,” said William Doyle, Novocure’s Executive Chairman. “Beginning with the top-line readout from the LUNAR study earlier this year, we expect a steady cadence of meaningful pivotal datasets through 2024. This is a transformational period for Novocure and, potentially, for the treatment of solid tumor cancers.”
Share:
More News
“This positive opinion from the CHMP highlights the significant unmet need and importance of effective treatment options for adult r/r B-ALL,” said Dr. Christian Itin, Chief Executive Officer of Autolus. “With FDA approval received in November 2024 and an MHRA conditional marketing authorization received in April 2025, we are on
“While we are disappointed by today’s outcome, we continue to believe our clinical data support UGN-102 for the treatment of recurrent LG-IR-NMIBC, a disease with no FDA-approved therapies,” said Liz Barrett, President and CEO of UroGen. “The FDA carefully considers the independent advice from ODAC, and we look forward to
“Columvi in combination with GemOx demonstrated a 41% reduction in risk of death in a Phase III, randomized, multiregional clinical trial, supporting its recent approval by the European Commission and inclusion in the U.S. National Comprehensive Cancer Network treatment guidelines as a category 1 preferred regimen,” said Levi Garraway, M.D.,
Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said, “Today’s approval marks another important milestone for InnoCare as we will celebrate our 10th anniversary this year. I would like to extend my sincere gratitude to all the physicians, patients, partners and employees who have contributed to this achievement. DLBCL
